Related by context. Frequent words. (Click for all words.) 62 randomized controlled clinical 62 prospective randomized controlled 61 subgroup analyzes 60 placebo controlled clinical 60 ALLHAT 60 prospective observational 59 RCTs 59 randomized trials 59 randomized controlled clinical trials 59 RTOG 59 randomized clinical trials 58 placebo controlled studies 58 meta analyzes 58 epidemiologic studies 58 TRITON TIMI 58 echocardiographic 58 multicenter 58 phase IIa 58 SPIRIT III 58 multicenter clinical 58 randomized controlled trials 57 multicentre 57 randomized clinical 57 Azedra 57 retrospective cohort study 57 ACC AHA 57 placebo controlled trials 57 multicenter study 56 secondary efficacy endpoints 56 clinical endpoints 56 randomized Phase III 56 pharmacodynamic effects 56 SWOG 56 PRECiSE 56 NSABP 56 substudy 56 ClinicalTrials.gov 56 clinical 56 immunohistochemical 56 carotid artery stenting 56 ADHF 56 generalizability 56 Neuradiab 55 longitudinal studies 55 bronchial thermoplasty 55 histopathological 55 randomized controlled 55 PROPEL trial 55 FDG PET 55 risk stratification 55 CAPRISA 55 AREDS 55 multicenter randomized 55 Phase 2b study 55 clinical trial 55 phase IIb 55 CR# vcMMAE 55 ENCODE 55 observational studies 54 ASCO Annual Meeting 54 ACTEMRA 54 EORTC 54 prospective randomized 54 darapladib 54 efficacy endpoints 54 CYPHER ® Stent 54 Rosuvastatin 54 Atherosclerosis Risk 54 placebo controlled randomized 54 Phase 2a trial 54 lipid lowering drugs 54 coronary revascularization 54 Acute Myocardial Infarction 54 kidney transplant recipients 54 MOZOBIL 54 Transcatheter Cardiovascular Therapeutics TCT 54 virologic 53 Multicenter 53 tanespimycin 53 clinically relevant 53 DSMB 53 active comparator 53 epidemiologic 53 angiographic 53 ponatinib 53 pharmacodynamic 53 carotid stenting 53 meta analysis 53 cardiometabolic risk 53 ARVO 53 cytogenetic 53 genotypic 52 STEMI patients 52 rNAPc2 52 Pharmacokinetic 52 Oncotype DX breast cancer 52 Lung Transplantation 52 Phase III randomized 52 registrational 52 double blinded placebo 52 deforolimus